ReviewBiomicrofluidics2017
Paper-based assays for urine analysis.
Review in Biomicrofluidics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Unveiling the state of the art: a systematic review and meta-analysis of paper-based microfluidic devices.Frontiers in bioengineering and biotechnology · 2024Pooled it
- Cellulose-based sensors for decentralized monitoring in precision agriculture.Nature communications · 2026Review
- Microfluidic platform for understanding Parkinson's disease and α-synuclein conformation.Translational neurodegeneration · 2025Review
- Metabolomics in cancer detection: A review of techniques, biomarkers, and clinical utility.BioMedicine · 2025Review
- Wicking pumps for microfluidics.Biomicrofluidics · 2024Review
- On the Application of Microfluidic-Based Technologies in Forensics: A Review.Sensors (Basel, Switzerland) · 2023Review
- Automated classification of urine biomarkers to diagnose pancreatic cancer using 1-D convolutional neural networks.Journal of biological engineering · 2023Article
- Recent Advances in Drug Delivery System Fabricated by Microfluidics for Disease Therapy.Bioengineering (Basel, Switzerland) · 2022Review
- Disposable paper-based microfluidics for fertility testing.iScience · 2022Review
- Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson's disease.Metabolic brain disease · 2022Review
- Design of Gold Nanoparticle Vertical Flow Assays for Point-of-Care Testing.Diagnostics (Basel, Switzerland) · 2022Review
- Toilet-based continuous health monitoring using urine.Nature reviews. Urology · 2022Review
- Review
- Design and Adoption of Low-Cost Point-of-Care Diagnostic Devices: Syrian Case.Micromachines · 2021Article
- Glioma-on-a-Chip Models.Micromachines · 2021Article
- Carbohydrate binding module-fused antibodies improve the performance of cellulose-based lateral flow immunoassays.Scientific reports · 2021Article
- Hemp-Based Microfluidics.Micromachines · 2021Article
- Long-term cyclic use of a sample collector for toilet-based urine analysis.Scientific reports · 2021Article
- Increasing the packing density of assays in paper-based microfluidic devices.Biomicrofluidics · 2021Review
- Machine learning-enabled multiplexed microfluidic sensors.Biomicrofluidics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A transformation of the healthcare industry is necessary and imminent: hospital-centered, reactive care will soon give way to proactive, person-centered care which focuses on individuals' well-being. However, this transition will only be made possible through scientific innovation. Next-generation technologies will be the key to developing affordable and accessible care, while also lowering the costs of healthcare. A promising solution to this challenge is low-cost continuous health monitoring; this approach allows for effective screening, analysis, and diagnosis and facilitates proactive medical intervention. Urine has great promise for being a key resource for health monitoring; unlike blood, it can be collected effortlessly on a daily basis without pain or the need for special equipment. Unfortunately, the commercial rapid urine analysis tests that exist today can only go so far-this is where the promise of microfluidic devices lies. Microfluidic devices have a proven record of being effective analytical devices, capable of controlling the flow of fluid samples, containing reaction and detection zones, and displaying results, all within a compact footprint. Moving past traditional glass- and polymer-based microfluidics, paper-based microfluidic devices possess the same diagnostic ability, with the added benefits of facile manufacturing, low-cost implementation, and disposability. Hence, we review the recent progress in the application of paper-based microfluidics to urine analysis as a solution to providing continuous health monitoring for proactive care. First, we present important considerations for point-of-care diagnostic devices. We then discuss what urine is and how paper functions as the substrate for urine analysis. Next, we cover the current commercial rapid tests that exist and thereby demonstrate where paper-based microfluidic urine analysis devices may fit into the commercial market in the future. Afterward, we discuss various fabrication techniques that have been recently developed for paper-based microfluidic devices. Transitioning from fabrication to implementation, we present some of the clinically implemented urine assays and their importance in healthcare and clinical diagnosis, with a focus on paper-based microfluidic assays. We then conclude by providing an overview of select biomarker research tailored towards urine diagnostics. This review will demonstrate the applicability of paper-based assays for urine analysis and where they may fit into the commercial healthcare market.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.